|
|
| ARAMIS Trial Demonstrates Significant Improvement in Overall Survival in nmCRPC |
| Neal Shore, MD, FACS |
| Neal Shore discusses the results of the phase III ARAMIS trial which randomized over 1,500 patients with non-metastatic castration-resistant prostate cancer to 600 mg of darolutamide orally twice daily with ADT, versus a placebo-controlled combination with ADT. |
|
|
|
|
|
|
|
|
|
|
|
|
Best of ASCO 2020 Prostate Cancer
|
|
A. Oliver Sartor, MD
|
| Oliver Sartor joins Alicia Morgans to speak about several prostate cancer studies making an impact on the diagnosis of prostate cancer and the treatment paradigm for this disease.
|
|
|
|
|
|
|
|
|
|
|
|
| 68Ga-PSMA PET: A Novel Imaging Technique Prior to Radical Prostatectomy in Men with Intermediate or High Risk Prostate Cancer |
| Thomas Hope, MD |
| In conversation with Charles Ryan, Thomas Hope details the prospective, multicenter single-arm open-label phase 3 imaging trial evaluating the accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy or definitive treatment and pelvic lymph node dissection. |
|
|
|
|
|
|
|
|
|
| Journal Club: Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer |
| Christopher J.D. Wallis, MD, Ph.D. and Zachary Klaassen, MD, MSc |
| Christopher Wallis and Zachary Klaassen host this journal club on "Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer," published by the HERO trial investigators in the New England Journal of Medicine simultaneously with the first presentation of the trial results at the ASCO 2020 annual meeting. |
|
|
|
|
|
|
|
|
|
|
|
|
| Low Carbohydrate Diets in Men with Recurrent Prostate Cancer: The CAPS2 Study |
| Stephen J. Freedland, MD |
| Stephen Freedland joins Alicia Morgans to discuss the Carbohydrate and Prostate Study 2 (CAPS2), a randomized controlled trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EDITOR SELECTED ABSTRACTS AND COMMENTARIES |
|
|
|
| A Randomized Controlled Trial of Video-Education or In-Person Genetic Counseling for Men with Prostate Cancer (ProGen) |
| Huma Q. Rana, MD |
| NCCN guidelines recommend genetic testing for men with advanced prostate cancer as well as men with certain high-risk features. Though timely cancer genetic testing is needed, this is challenging as it increases patient appointment burden and may be limited by access to trained clinical geneticists. Therefore, the authors of this study conducted a randomized clinical trial to compare video-based education with in-person genetic counseling in men with prostate cancer. |
|
|
|
|
|
| Darolutamide Demonstrates Significant Improvement in Overall Survival in nmCRPC -The ARAMIS Trial
|
| Karim Fizazi, MD, Ph.D.
|
Karim Fizazi's presentation provides updated data on the ARAMIS study including the much anticipated overall survival results at the 2020 American Society of Clinical Oncology virtual scientific meeting. Results of ARAMIS led to darolutamide a unique androgen receptor inhibitor, to be FDA approved in July 2019 for the treatment of non-metastatic castration-resistant prostate cancer. |
|
|
|
|
|
|
